<div>In January of this year, Adam Surkan at the age of only 41, received a devastating diagnosis of Stage IV pancreatic cancer. Given his age, the initial prognosis was particularly challenging, with medical experts indicating that only 50% of patients with this type of cancer reach the one-year mark. The only treatment initially presented to Adam was palliative care.
</div>
<div><br />
</div>
<div><br />
</div>
<div><br />
</div>
<div>Despite the difficult news, Adam has approached his journey with remarkable positivity and determination, resolute in his fight against the cancer. He recently learned about a progressive immunotherapy treatment with a high success rate for aggressive cancers, including his specific diagnosis. This innovative immunotherapy involves developing a patient-specific vaccine, contingent upon Adam meeting specific biological and medical indicators to ensure a high probability of success.
</div>
<div><br />
</div>
<div><br />
</div>
<div><br />
</div>
<div>After extensive research, Adam applied to a compassionate care cancer clinic overseas, which has demonstrated success in treating some pancreatic cancer patients. The protocol used at this clinic is currently in clinical trials in the United States. It involves harvesting tumor tissue to create a custom-made vaccine designed to empower the body's immune system to combat the disease. As with any personalized treatment, the cost is substantial. However, Adam and his family have made the courageous decision to pursue this option, hoping for remission or, at minimum, a significant period of disease stability. Notably, some patients undergoing this procedure have experienced up to seven years of extended life, a remarkable outcome when considering that only 3% of Stage IV pancreatic cancer patients typically reach the five-year mark.
</div>
<div><br />
</div>
<div><br />
</div>
<div><br />
</div>
<div>Crucially, this immunotherapy cannot be administered concurrently with traditional chemotherapy. Consequently, after many challenging rounds of chemotherapy, Adam has suspended that treatment to focus on the immunotherapy's potential for significant outcomes, rather than the palliative nature of his previous care. On a positive note, this decision has allowed Adam to enjoy a few summer months surrounded by family and friends while the clinical team plans his treatment and conducts necessary tests and biopsies.
</div>
<div><br />
</div>
<div><br />
</div>
<div><br />
</div>
<div>The Path Forward: Funding and Support
</div>
<div><br />
</div>
<div>This cutting-edge treatment is not available in Canada and is not covered by Canadian medical insurance or services. Unfortunately, the estimated cost of $110,000 USD, plus travel and related expenses, is beyond Adam's personal financial means. His family has explored various funding avenues through agencies and charities, but these efforts have yet to yield success. Based on recommendations from multiple sources, and with the encouragement of friends, we have established this fundraising page to help Adam and his family cover these significant costs.
</div>
<div><br />
</div>
<div><br />
</div>
<div><br />
</div>
<div>We would be incredibly grateful for any support you can offer. Should there be any remaining funds after covering Adam’s ongoing treatments and expenses, they will be directed to assist other cancer patients, clinics, or charities.
</div>
<div><br />
</div>
<div>Adam wants to acknowledge his family and close friends who have already committed funds for his treatment.
</div>

Barbara Tafilaj

Anonymous

Allen Lazenby Jr

Mike Rendell

romuald et Eliane favre

Charlotte Pak

Yanik Boily

Nancie Gantenbein

Cynthia Medrek

Jon Breisnes

Todd Cooper

Annita Furzer

Sabine Habart

David Loucks

Daisy St. Croix

Ron and Marilyn Simpson

Suzanne Bailey

Tom Havard

Tracy Mazgaj

Immunocine Cancer Therapy for Adam Surkan

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

currencyCode

Money Box Donation List Prompt Experiment Audience

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

NPO upsell education category

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

NPO recommendations prod

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

categoryGroup

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

NPO upsell animals category

NPO upsell disaster relief category

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

NPO upsell essential needs category

NPO upsell medical category

userCurrencyCode

Localized Currency

NPO upsell cancer category

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Immunocine Cancer Therapy for Adam Surkan

Still $133,258 to go. Help us build momentum.